Location: Toronto, Canada
CEO: David S. Young
CFO: Warren Whitehead
Board of Directors: David S. Young, Carl L. Gordon, Joseph Zakrzewski, James Rae, Graham Strachan

- ARIUS developed a proprietary antibody platform called FunctionFIRST™, which rapidly identifies and selects antibodies based on their functional ability to affect disease before progressing into clinical development.

- Aquilo helped ARIUS evaluate multiple strategic options, from single product licensing deals to broad platform deals to a full acquisition of the company.

- The final acquisition price of C$2.44/share (transaction value of approximately US$184m) represented a premium of:

• 44% to the 20-day volume-weighted average closing price ending May 15, 2008 (the last trading day prior to ARIUS’ announcement that third parties had shown interest in ARIUS and its technologies); and
• 132% over the closing price on the day ARIUS engaged Aquilo.